Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth Milestone

Stock Information for Nuwellis Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Nuwellis Inc.

Nuwellis Completes Acquisition of Rendiatech
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results
Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy
Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
Nuwellis Appoints Carisa Schultz as Chief Financial Officer
Nuwellis Announces $5 Million Private Placement and Warrant Inducement Transaction, Priced At-The-Market
Nuwellis Enters into Definitive Agreement to Acquire Rendiatech, Advancing Its Cardiorenal Portfolio Strategy

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.